BABianca L. Artiaga

Bianca L. Artiaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bianca L. Artiaga has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • John P. Driver

    Division of Animal Sciences, University of Missouri, Columbia, USA

    5 shared publications
  • Guan Yang

    Department of Animal Sciences, University of Florida, Gainesville, FL, USA

    4 shared publications
  • Shahram Salek-Ardakani

    Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA

    3 shared publications
  • John A. Lednicky

    Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA

    2 shared publications
  • Jürgen A. Richt

    Diagnostic Medicine and Pathobiology and Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA

    2 shared publications
  • Timothy J. Hackmann

    Department of Animal Science, University of Florida, Gainesville, FL, USA

    2 shared publications

Latest Publications

  • Open Access

    Rapid control of pandemic H1N1 influenza by targeting NKT-cells

    by Bianca L. Artiaga, Guan Yang, Tarun E. Hutchinson, Julia C. Loeb, Jürgen A. Richt, John A. Lednicky, Shahram Salek-Ardakani, John P. Driver

    Swine influenza A viruses (IAV) are a major cause of respiratory disease in pigs and humans. Currently approved anti-influenza therapies directly target the virus, but these approaches are losing effectiveness as new viral strains quickly develop drug resistance. To over come this challenge, there is an urgent need for more effective antiviral drugs. Here we tested the anti-influenza efficacy of the invariant natural killer T (NKT) cell superagonist, α-galactosylceramide (α-GalCer), which stimulates a wide array of anti-viral immune responses. We show that intranasal but not systemic administration of α-GalCer to piglets infected with pandemic A/California/04/2009 (CA04) H1N1 IAV ameliorated disease symptoms and resulted in the restoration of weight gain to the level of uninfected pigs. Correspondingly, viral titers in the upper-and lower-respiratory tract were reduced only in piglets that had received intranasal α-GalCer. Most significantly, lung inflammation as a consequence of virus persistence was largely prevented when NKT-cells were targeted via the respiratory route. Thus, targeting mucosal NKT-cells may provide a novel and potent platform for improving the course of disease in swine infected with seasonal and pandemic influenza viruses, and leads to the suggestion that this may also be true in humans and therefore deserves further study.


  • Open Access

    α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant

    by Bianca L. Artiaga, Guan Yang, Timothy J. Hackmann, Qinfang Liu, Jürgen A. Richt, Shahram Salek-Ardakani, William L. Castleman, John A. Lednicky, John P. Driver

    Natural killer T (NKT) -cells activated with the glycolipid ligand α-galactosylceramide (α-GalCer) stimulate a wide array of immune responses with many promising immunotherapeutic applications, including the enhancement of vaccines against infectious diseases and cancer. In the current study, we evaluated whether α-GalCer generates protective immunity against a swine influenza (SI) virus infection when applied as an intramuscular vaccine adjuvant. Immunization of newly weaned piglets with UV-killed pandemic H1N1 A/California/04/2009 (kCA04) SI virus and α-GalCer induced high titers of anti-hemagglutinin antibodies and generated virus-specific T cells that localized in intrapulmonary airways and in alveolar walls. Vaccination with α-GalCer resulted in a systemic increase in NKT-cell concentrations, including in the respiratory tract, which was associated with complete inhibition of viral replication in the upper and lower respiratory tract and much reduced viral shedding. These results indicate that NKT-cell agonists could be used to improve swine vaccine formulations in order to reduce the clinical signs of SI infection and limit the spread of influenza viruses amongst commercial pigs.


  • Targeted disruption of CD1d prevents NKT cell development in pigs

    by Guan Yang, Bianca L. Artiaga, Timothy J. Hackmann, Melissa S. Samuel, Eric M. Walters, Shahram Salek-Ardakani, John P. Driver

    Studies in mice genetically lacking natural killer T (NKT) cells show that these lymphocytes make important contributions to both innate and adaptive immune responses. However, the usefulness of murine models to study human NKT cells is limited by the many differences between mice and humans, including that their NKT cell frequencies, subsets, and distribution are dissimilar. A more suitable model may be swine that share many metabolic, physiological, and growth characteristics with humans and are also similar for NKT cells. Thus, we analyzed genetically modified pigs made deficient for CD1d that is required for the development of Type I invariant NKT (iNKT) cells that express a semi-invariant T-cell receptor (TCR) and Type II NKT cells that use variable TCRs. Peripheral blood analyzed by flow cytometry and interferon-γ enzyme-linked immuno spot assays demonstrated that CD1d-knockout pigs completely lack iNKT cells, while other leukocyte populations remain intact. CD1d and NKT cells have been shown to be involved in shaping the composition of the commensal microbiota in mice. Therefore, we also compared the fecal microbiota profile between pigs expressing and lacking NKT cells. However, no differences were found between pigs lacking or expressing CD1d. Our results are the first to show that knocking-out CD1d prevents the development of NKT cells in a non-rodent species. CD1d-deficient pigs should offer a useful model to more accurately determine the contribution of NKT cells for human immune responses. They also have potential for understanding how NKT cells impact the health of commercial swine.


  • Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs

    by Bianca L. Artiaga, Robert L. Whitener, Charles R. Staples, John P. Driver